# Perioperative Therapy for Hepatocellular Carcinoma

> **NCT04653389** · PHASE2 · TERMINATED · sponsor: **Zhejiang University** · enrollment: 10 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab Injection
- **DRUG:** TACE
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04653389
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-26
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The treatment efficacy was not satisfactory.
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04653389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04653389, "Perioperative Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04653389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*